PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tamsulosin with solifenacin - Benign prostatic hyperplasia
PAD Profile : Tamsulosin with solifenacin - Benign prostatic hyperplasia
Keywords :
BPH, LUTS, urinary retention
Brand Names Include :
Vesomni
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tadalafil
- Tamsulosin and dutasteride hydrochloride
- Alfuzosin hydrochloride
- Tamsulosin hydrochloride
- Doxazosin
- Terazosin hydrochloride
- Indoramin
- Prazosin hydrochloride
- Sildenafil
- Avanafil
- Vardenafil
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
18 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of the combination product Vesomni® (tamsulosin & solifenacin) as a treatment option for lower urinary tract symptoms in men and has assigned a BLACK traffic light status to this treatment.
Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention